Abstract
Original language | English |
---|---|
Pages (from-to) | 873-889 |
Number of pages | 17 |
Journal | Journal of Thoracic Oncology |
Volume | 17 |
Issue number | 7 |
DOIs | |
Publication status | Published - Jul 2022 |
Access to Document
Other files and links
Fingerprint
Dive into the research topics of 'Medical and Surgical Care of Patients With Mesothelioma and Their Relatives Carrying Germline BAP1 Mutations'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Journal of Thoracic Oncology, Vol. 17, No. 7, 07.2022, p. 873-889.
Research output: Contribution to journal › Review article › peer-review
TY - JOUR
T1 - Medical and Surgical Care of Patients With Mesothelioma and Their Relatives Carrying Germline BAP1 Mutations
AU - Carbone, Michele
AU - Pass, Harvey I.
AU - Ak, Guntulu
AU - Alexander, H. Richard
AU - Baas, Paul
AU - Baumann, Francine
AU - Blakely, Andrew M.
AU - Bueno, Raphael
AU - Bzura, Aleksandra
AU - Cardillo, Giuseppe
AU - Churpek, Jane E.
AU - Dianzani, Irma
AU - De Rienzo, Assunta
AU - Emi, Mitsuru
AU - Emri, Salih
AU - Felley-Bosco, Emanuela
AU - Fennell, Dean A.
AU - Flores, Raja M.
AU - Grosso, Federica
AU - Hayward, Nicholas K.
AU - Hesdorffer, Mary
AU - Hoang, Chuong D.
AU - Johansson, Peter A.
AU - Kindler, Hedy L.
AU - Kittaneh, Muaiad
AU - Krausz, Thomas
AU - Mansfield, Aaron
AU - Metintas, Muzaffer
AU - Minaai, Michael
AU - Mutti, Luciano
AU - Nielsen, Maartje
AU - O'Byrne, Kenneth
AU - Opitz, Isabelle
AU - Pastorino, Sandra
AU - Pentimalli, Francesca
AU - de Perrot, Marc
AU - Pritchard, Antonia
AU - Ripley, Robert Taylor
AU - Robinson, Bruce
AU - Rusch, Valerie
AU - Taioli, Emanuela
AU - Takinishi, Yasutaka
AU - Tanji, Mika
AU - Tsao, Anne S.
AU - Tuncer, A. Murat
AU - Walpole, Sebastian
AU - Wolf, Andrea
AU - Yang, Haining
AU - Yoshikawa, Yoshie
AU - Zolondick, Alicia
AU - Schrump, David S.
AU - Hassan, Raffit
N1 - Funding Information: Disclosure: Drs. Carbone and Yang report receiving funding from the National Institute of Environmental Health Sciences 1R01ES030948-01, the National Cancer Institute (NCI) 1R01CA237235-01A1 (and 1R01CA198138 (Dr. Carbone), the U.S. Department of Defense W81XWH-16-1-0440 (Drs. Yang, Carbone, and Pass), and the UH Foundation through donations from the following: the Riviera United-4-a Cure (Drs. Carbone and Yang), the Melohn Family Endowment, the Honeywell International Inc., the Germaine Hope Brennan Foundation, and the Maurice and Joanna Sullivan Family Foundation (Dr. Carbone). Dr. Carbone has a patent issued for BAP1. Drs. Carbone and Yang have two patents issued for HMGB1. Dr. Carbone is a board-certified pathologist who provides consultation for pleural pathology, including medical-legal. Drs. Pass and Yang report receiving funding from the Early Detection Research Network NCI 5U01CA214195-04. Dr. Pass reports receiving funding from Genentech and Belluck & Fox, LLP. Dr. Baas reports receiving grants and other from Bristol Myers Squibb and Merck Sharp & Dohme; and other from Aldeyra, BeiGene, Pfizer, and AstraZeneca, outside of the submitted work. Dr. Bueno reports receiving grants from MedGenome, Roche, Verastem, Gritstone, Epizyme, Siemens, Merck, NCI, U.S. Department of Defense, National Institutes of Health (NIH), and Genentech, outside of the submitted work. Dr. Bueno has also a patent 7,622,260 licensed to Brigham and Women's Hospital (BWH), a patent 8,450,057 licensed to BWH, a patent 8,551,700 licensed to BWH, and a patent 9,446,050 licensed to BWH and Patents/Equity in Navigation Sciences. Dr. Churpek reports receiving other from UpToDate, Inc., outside of the submitted work. Dr. Dianzani has been appointed by the public prosecution office to discuss court cases with asbestos-related neoplasms. Dr. Fennell reports receiving nonfinancial support from Clovis Oncology, Eli Lilly, Roche, and GlaxoSmithKline; grants and personal fees from Bristol Myers Squibb; personal fees and nonfinancial support from Merck Sharp & Dohme; personal fees from Targovax and Inventiva; nonfinancial support from Atlas and Imagen Therapeutics; and grants from Bayer and Astex Therapeutics, outside of the submitted work. Dr. Hayward reports receiving grants from the National Health and Medical Research Council, during the conduct of the study. Dr. Kindler reports receiving personal fees, nonfinancial support, and other from AstraZeneca and Merck; personal fees and other from Bayer, Bristol-Myers Squibb, Deciphera, and Inhibrx; personal fees and nonfinancial support from Boehringer-Ingelheim, Paredox Therapeutics, and Inventiva; personal fees from Kyowa and Novocure; and other from Aduro, GlaxoSmithKline, Harpoon, Lilly, Polaris, Verastem, Blueprint, and Tesaro, outside of the submitted work. Dr. Kittaneh reports being employed by ICON Clinical Research. Dr. Mansfield reports having consulting or advisory role (honoraria to institution) from Janssen, Genentech, Bristol Myers Squibb, AbbVie, and AstraZeneca; receiving travel, accommodation, and expenses from AbbVie and Roche; receiving research funding from Novartis, NIH, and Mark Foundation; and serving in the board as nonremunerated member of the Mesothelioma Applied Research Foundation. Dr. O'Byrne has received advisory board and/or speaker bureau and/or meeting travel/registration support from Bristol Myers Squibb, Merck Sharp & Dohme, Roche, and AstraZeneca. Dr. Opitz reports receiving personal fees from Roche and AstraZeneca and grants from Roche and Medtronic, outside of the submitted work. Dr. de Perrot reports receiving personal fees from Bayer, Actelion, and AstraZeneca, outside of the submitted work. Dr. Rusch reports receiving grants from Genelux, Inc., and Genentech; and other from DaVinci Surgery, Bristol Myers Squibb, and NIH/Coordinating Center for Clinical Trials, outside of the submitted work. Dr. Tsao reports receiving personal fees from Genentech, during the conduct of the study; receiving personal fees from Bristol Myers Squibb, Eli Lilly, Roche, Novartis, Ariad, EMD Serono, Merck, Seattle Genetics, AstraZeneca, Boehringer-Ingelheim, Sellas Life Science, and Takeda; and receiving grants from Millennium, Polaris, Epizyme, and EMD Serono, outside of the submitted work. Dr. Hassan reports receiving other from Bayer AG, TCR2 Therapeutics, and AstraZeneca, outside of the submitted work. The remaining authors declare no conflict of interest. Funding Information: Disclosure: Drs. Carbone and Yang report receiving funding from the National Institute of Environmental Health Sciences 1R01ES030948-01 , the National Cancer Institute ( NCI ) 1R01CA237235-01A1 (and 1R01CA198138 (Dr. Carbone), the U.S. Department of Defense W81XWH-16-1-0440 (Drs. Yang, Carbone, and Pass), and the UH Foundation through donations from the following: the Riviera United-4-a Cure (Drs. Carbone and Yang), the Melohn Family Endowment, the Honeywell International Inc., the Germaine Hope Brennan Foundation, and the Maurice and Joanna Sullivan Family Foundation (Dr. Carbone). Dr. Carbone has a patent issued for BAP1. Drs. Carbone and Yang have two patents issued for HMGB1. Dr. Carbone is a board-certified pathologist who provides consultation for pleural pathology, including medical-legal. Drs. Pass and Yang report receiving funding from the Early Detection Research Network NCI 5U01CA214195-04. Dr. Pass reports receiving funding from Genentech and Belluck & Fox, LLP . Dr. Baas reports receiving grants and other from Bristol Myers Squibb and Merck Sharp & Dohme ; and other from Aldeyra , BeiGene , Pfizer , and AstraZeneca , outside of the submitted work. Dr. Bueno reports receiving grants from MedGenome , Roche , Verastem , Gritstone , Epizyme , Siemens , Merck , NCI , U.S. Department of Defense , National Institutes of Health (NIH), and Genentech, outside of the submitted work. Dr. Bueno has also a patent 7,622,260 licensed to Brigham and Women's Hospital (BWH), a patent 8,450,057 licensed to BWH, a patent 8,551,700 licensed to BWH, and a patent 9,446,050 licensed to BWH and Patents/Equity in Navigation Sciences. Dr. Churpek reports receiving other from UpToDate, Inc., outside of the submitted work. Dr. Dianzani has been appointed by the public prosecution office to discuss court cases with asbestos-related neoplasms. Dr. Fennell reports receiving nonfinancial support from Clovis Oncology , Eli Lilly, Roche , and GlaxoSmithKline; grants and personal fees from Bristol Myers Squibb; personal fees and nonfinancial support from Merck Sharp & Dohme; personal fees from Targovax and Inventiva; nonfinancial support from Atlas and Imagen Therapeutics; and grants from Bayer and Astex Therapeutics , outside of the submitted work. Dr. Hayward reports receiving grants from the National Health and Medical Research Council , during the conduct of the study. Dr. Kindler reports receiving personal fees, nonfinancial support, and other from AstraZeneca and Merck; personal fees and other from Bayer, Bristol-Myers Squibb, Deciphera, and Inhibrx; personal fees and nonfinancial support from Boehringer-Ingelheim, Paredox Therapeutics, and Inventiva; personal fees from Kyowa and Novocure; and other from Aduro, GlaxoSmithKline, Harpoon, Lilly, Polaris, Verastem, Blueprint, and Tesaro, outside of the submitted work. Dr. Kittaneh reports being employed by ICON Clinical Research. Dr. Mansfield reports having consulting or advisory role (honoraria to institution) from Janssen, Genentech, Bristol Myers Squibb, AbbVie, and AstraZeneca; receiving travel, accommodation, and expenses from AbbVie and Roche; receiving research funding from Novartis , NIH , and Mark Foundation; and serving in the board as nonremunerated member of the Mesothelioma Applied Research Foundation . Dr. O’Byrne has received advisory board and/or speaker bureau and/or meeting travel/registration support from Bristol Myers Squibb , Merck Sharp & Dohme , Roche , and AstraZeneca . Dr. Opitz reports receiving personal fees from Roche and AstraZeneca and grants from Roche and Medtronic , outside of the submitted work. Dr. de Perrot reports receiving personal fees from Bayer, Actelion, and AstraZeneca, outside of the submitted work. Dr. Rusch reports receiving grants from Genelux, Inc., and Genentech; and other from DaVinci Surgery, Bristol Myers Squibb, and NIH/Coordinating Center for Clinical Trials, outside of the submitted work. Dr. Tsao reports receiving personal fees from Genentech, during the conduct of the study; receiving personal fees from Bristol Myers Squibb, Eli Lilly, Roche, Novartis, Ariad, EMD Serono, Merck, Seattle Genetics, AstraZeneca, Boehringer-Ingelheim, Sellas Life Science, and Takeda; and receiving grants from Millennium, Polaris, Epizyme, and EMD Serono , outside of the submitted work. Dr. Hassan reports receiving other from Bayer AG, TCR2 Therapeutics, and AstraZeneca, outside of the submitted work. The remaining authors declare no conflict of interest. Publisher Copyright: © 2022 International Association for the Study of Lung Cancer
PY - 2022/7
Y1 - 2022/7
N2 - The most common malignancies that develop in carriers of BAP1 germline mutations include diffuse malignant mesothelioma, uveal and cutaneous melanoma, renal cell carcinoma, and less frequently, breast cancer, several types of skin carcinomas, and other tumor types. Mesotheliomas in these patients are significantly less aggressive, and patients require a multidisciplinary approach that involves genetic counseling, medical genetics, pathology, surgical, medical, and radiation oncology expertise. Some BAP1 carriers have asymptomatic mesothelioma that can be followed by close clinical observation without apparent adverse outcomes: they may survive many years without therapy. Others may grow aggressively but very often respond to therapy. Detecting BAP1 germline mutations has, therefore, substantial medical, social, and economic impact. Close monitoring of these patients and their relatives is expected to result in prolonged life expectancy, improved quality of life, and being cost-effective. The co-authors of this paper are those who have published the vast majority of cases of mesothelioma occurring in patients carrying inactivating germline BAP1 mutations and who have studied the families affected by the BAP1 cancer syndrome for many years. This paper reports our experience. It is intended to be a source of information for all physicians who care for patients carrying germline BAP1 mutations. We discuss the clinical presentation, diagnostic and treatment challenges, and our recommendations of how to best care for these patients and their family members, including the potential economic and psychosocial impact.
AB - The most common malignancies that develop in carriers of BAP1 germline mutations include diffuse malignant mesothelioma, uveal and cutaneous melanoma, renal cell carcinoma, and less frequently, breast cancer, several types of skin carcinomas, and other tumor types. Mesotheliomas in these patients are significantly less aggressive, and patients require a multidisciplinary approach that involves genetic counseling, medical genetics, pathology, surgical, medical, and radiation oncology expertise. Some BAP1 carriers have asymptomatic mesothelioma that can be followed by close clinical observation without apparent adverse outcomes: they may survive many years without therapy. Others may grow aggressively but very often respond to therapy. Detecting BAP1 germline mutations has, therefore, substantial medical, social, and economic impact. Close monitoring of these patients and their relatives is expected to result in prolonged life expectancy, improved quality of life, and being cost-effective. The co-authors of this paper are those who have published the vast majority of cases of mesothelioma occurring in patients carrying inactivating germline BAP1 mutations and who have studied the families affected by the BAP1 cancer syndrome for many years. This paper reports our experience. It is intended to be a source of information for all physicians who care for patients carrying germline BAP1 mutations. We discuss the clinical presentation, diagnostic and treatment challenges, and our recommendations of how to best care for these patients and their family members, including the potential economic and psychosocial impact.
KW - Asbestos
KW - BAP1
KW - Cancer genetics
KW - Germline mutations
KW - Mesothelioma
KW - Tumor predisposition syndromes
UR - http://www.scopus.com/inward/record.url?scp=85130361193&partnerID=8YFLogxK
U2 - 10.1016/j.jtho.2022.03.014
DO - 10.1016/j.jtho.2022.03.014
M3 - Review article
C2 - 35462085
AN - SCOPUS:85130361193
SN - 1556-0864
VL - 17
SP - 873
EP - 889
JO - Journal of Thoracic Oncology
JF - Journal of Thoracic Oncology
IS - 7
ER -